Harold H. Shlevin

Dr. Shlevin is the retired former chief executive officer (CEO) and president of Galectin Therapeutics, now working with the Company on a consulting basis to help guide the Company’s ongoing Phase 2b/3 NASH-RX clinical trial. He is a bioscience industry executive with 25 years of senior management experience in the development and commercialization of pharmaceuticals, diagnostics, and vaccines. Before joining Galectin Therapeutics as a chief operating officer (COO) in 2012 and assuming the role of CEO and president in 2018, Dr. Shlevin led Georgia Institute of Technology’s Advanced Technology Development Center (ATDC) as principal and manager of bioscience commercialization efforts, where he served as a catalyst for new bioscience startup companies. His leadership roles have included president and chief executive officer of Solvay Pharmaceuticals, where he oversaw the successful launch of the first topical testosterone gel product in the US; co-founder of CIBA Vision Ophthalmics, a specialty ophthalmic drug company, where he headed efforts leading to the approval of the first non-steroidal agent for the treatment of ocular inflammation and several other drug products; founder, president, and chief executive officer of Tikvah Therapeutics, a company focused on the clinical development of therapeutics for the treatment of neurological diseases; and vice president and head of operations and commercial development for Altea Therapeutics Corporation, a clinical-stage drug delivery company with platform technology applicable to the transdermal delivery of biologics.